Trop2 CAR-NK for advanced lung cancer that has returned
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new treatment called Trop2 CAR-NK, which uses your own immune cells modified to attack lung cancer cells that have a protein called Trop2. It is for people with advanced non-small cell lung cancer that has not responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old.
- You have advanced non-small cell lung cancer (stage IIIB or IV) that has come back or not responded to treatment.
- You have tried and failed at least one standard treatment for your type of lung cancer (e.g., immunotherapy, targeted therapy, or chemotherapy).
- Your tumor shows at least 50% of the Trop2 protein (a marker on cancer cells).
- You do not have active or untreated brain metastases, serious infections, or major heart/lung problems.
- You are willing to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new imaging scan (two types of PET/CT) to see how well it tracks tumor response to a TROP2-targeted drug in people with EGFR-mutant lung cancer that stopped responding to standard pills. It aims to improve how doctors measure treatment success.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
This research study analyzes lung cancer tissue samples to understand a protein called TROP2 and how it might help guide treatment decisions. You may qualify if you have non-squamous lung cancer and haven't received prior systemic chemotherapy or immunotherapy for advanced disease.
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
This trial tests a medicine called TROP2-ADC, which targets a protein on cancer cells to kill them. It is for people with advanced high-grade neuroendocrine tumors that have not responded to standard treatments. The goal is to see if this drug can shrink tumors or slow their growth.
Hear when a new Non-Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.